subclones expressing the murine ecotropic receptor were kind gifts from Dr. M. Eilers (Marburg, Germany). The SK-N-SH subclone ectopically expressing the murine ecotropic receptor was generated for this study; SK-N-BE and SK-N-FI were from the laboratory collection of Dr R. Versteeg.
The culture condition and retroviral infection of E14T mouse ES cells are described below. All other cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 8% heatinactivated fetal calf serum (FCS), penicillin and streptomycin. F9 cells were cultured on gelatin-treated tissue culture plastic.
Retroviral transductions were performed using Phoenix cells as producers of viral supernatants as described (www.stanford.edu/group/nolan/retroviral_systems/phx.html). Infected cells were selected for successful retroviral integration using 1-2 ug/ml of puromycin. Lentiviral shRNAs targeting human ZNF423 were obtained from Sigma-Aldrich (TRC shRNA Library). Recombinant lentiviruses were produced by transient transfection of the 293T cells using Lipofectamine 2000 (Invitrogen) with appropriate amounts of the shRNA vector and three packaging vectors: pMD2G, a plasmid expressing the VSVg envelope gene, the pRRE packaging vector, and pRSV/REV vector. The supernatants were collected 48 and 72 hours after transfection and filtered through a 0.45-μM filter and neuroblastoma cells were transduced with the virus for 48h.
ES Cell Culture and Viral Infection
E14T ES cells (Li et al, 1998) were cultured on gelatin-coated tissue culture plastic. Cells were grown in 60% BRL medium plus Leukemia Inhibitory Factor (LIF) (60% BRL, 40% Complete medium including 2 mM L-glutamine (Invitrogen), 0.1 mM 2-mecaptoethanol and 10 u/ml LIF (Esgro LIF, Invitrogen)). Complete medium consists of GMEM (Glasgow modified Eagle's medium), 2 mM L-glutamine (Invitrogen), 1mM sodium pyruvate (Invitrogen), 0.1 mM non-essential amino acids (Invitrogen),10% FCS (fetal calf serum, PAA, Pasching, Germany), 100 μg/ml penicillin and 100 μg/ml streptomycin (Invitrogen). BRL was obtained by collecting CM that was conditioned for a week onto Buffalo Rat Liver cells.
E14T cells were seeded at 4-8 x 10 4 cells/well in 6-wells plates. The next day, retrovirus (collected in CM) was mixed with infection medium (100% BRL, 20 u/ml LIF, 4 mM L-glutamine, 0.2 mM 2-mercaptoethanol, 1.6 μg/ml mg/mL polybrene) and put on the E14T cells in duplicate. Virus was kept on the cells for 4 to 6 hours, and then the infection medium was replaced by 60% BRL plus LIF overnight. Three more rounds of infection were performed and on the last day, selection on 4 μg/ml puromycin was started.
Cell Proliferation Assays
Cells were seeded into 6-well plates (0.5-2 x10 4 cells/well) and cultured both in the absence and presence of RA. For the fast proliferating F9 cells, the plated cells were trypsinized after 2 days of RA treatment. 10%of cells were replated and the treatment with RA was continued. This replating step to sensitize F9 cells to the RA treatment was not applied to the other cell lines shown. At the endpoints of colony formation assays, cells were fixed, stained with crystal violet or Coomassie Blue and photographed. Crystal violet stain was then extracted using 10% Acetic Acid and quantified at OD 590nm. The ES cells were stained for alkaline phosphatase (AP) according to manufacturers' instructions. The growth curves were performed according to the standard 3T3 protocol. All relevant assays were performed independently at least three times.
Plasmids
All retroviral shRNA vectors were generated by ligating synthetic oligonucleotides against the target genes into in the pRISC retroviral vector as described (Brummelkamp et al., 2002) . The TCR lentiviral shRNA vectors against hZNF423: shhZNF423#3 and shhZNF423#4 (TRCN0000018173, TRCN0000018177), and the non-target control shRNA (SH002) were from Sigma. The RNAi target sequences for this study are listed in the table 1 of the Supplemental Data. The RARE-Luciferase reporter and pCS2-FLAG-hZNF423ΔN were as described previously (Epping et al., 2005; Hata et al., 2000) . The EcoRI fragment containing full-length hZNF423 from pCR4-hZNF423 (Geneservice) was cloned into the pcDNA3.1+ vector to generate pcDNA-hZNF423. The same fragment was cloned into pMSCV-GFP-PGKlinker-IRES2-PURO to generate pMSCV-GFP-PGK-hZNF423-IRES2-PURO. The linker sequence was AGCTTGAATTCCCAGATCTCCCTCGAGCCGTCGACA. EcoRI fragments containing full-length hRXRα or hRARα were obtained from pSG5-hRXRα or pSG5-hRARα and cloned into pGEX_2T vector to generate GST-hRXRα and GST-hRARα fusions.
Quantitative RT-PCR
qRT-PCR assays were carried out to measure mRNA levels of genes using 7500 Fast Real-Time PCR System as described (Kortlever et al., 2006) . Relative mRNA levels of each gene shown were normalized to the expression of house keeping gene GAPDH. The Taqman probes for Zfp423 (Mm00473699_m1),
were purchased from Applied Biosystems (Foster City, CA, USA). The sequences of the primers for assays using SYBR® Green master mix are list in table 1 of the Supplemental Data.
Microarray Analysis
For the AMC cohort, total RNA of the neuroblastoma tumors was extracted using the Trizol reagent (Invitrogen) according to the manufacturer's protocol. RNA concentration was determined using the NanoDrop ND-1000, and quality was determined using the RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer (Agilent Technologies). Affymetrix microarray analysis, fragmentation of RNA, labeling, hybridization to HG-U133 Plus 2.0 microarrays, and scanning were carried out according to the manufacturer's protocol (Affymetrix, Inc.). The expression data were normalized with the MAS5.0 algorithm within the GCOS program of Affymetrix. Target intensity was arbitrarily set to 100 (alpha 1 = 0.04 and alpha 2 = 0.06). The ZNF423 cut-off value of 353.6 was determined as described in Experimental Procedures.
The ZNF423 expression data of the second independent cohort was also obtained using Affymetrix platform (from U133A gene chip microarray) as described (Asgharzadeh et al., 2006) . For the validation study, ZNF423 expression of this second independent cohort was first normalized with MAS5.0 algorithm. By selecting the probe sets present at the U133A part of the U133 Plus 2.0 chip, the ZNF423 expression data of AMC cohort was re-normalized to U133A values for direct comparison with the second data set. The ZNF423 cut-off value (353.6) of the AMC cohort in U133 Plus 2.0 setting was translated into 178.2 in U133A setting. This translated ZNF423 cut-off value was then used to classify the patients from the second independent cohort for the progression-free survival analysis.
The microarray analysis of SH-SY5Y neuroblastoma cells expressing MSCV control or MSCV-ZNF423 was performed using Illumina platform (Human WG-6 v3.0 expression beadchip). The detail protocol information can be found at http://microarrays.nki.nl/. For the comparison analysis between the Illumina and Affymetrix platforms, only the genes that can be mapped to both platforms were included.
Supplemental References
Asgharzadeh, S., Pique-Regi, R., Sposto, R., Wang, H., Yang, Y., Shimada, H., Matthay, K., Buckley, J., Ortega, A., and Seeger, R. C. In addition to Rarβ and Crabp2 (data not shown and See also Figure 3D and E), transcriptional activation of RA target genes Cyp26a1, Hnf1b, Cdx1, Hoxa1, Hoxa3 and Hoxb5 in F9 cells also requires Zfp423. mRNA expression analysis in F9 cells expressing shRNAs targeting Zfp423, Rxrα or GFP after 1 μM RA stimulation for 48 hours after serum-starved for 72 hours. In the absence of RA, the expression levels of these target genes were not significantly affected by shZfp423 (also data not shown). Statistical test to assess the probability of observing 142 genes (see Table S4 ) with a significant difference (t-test p-value <0.01) in the "ZNF423 high" versus the "ZNF423 low" cohort of 102 neuroblastomas tumors described by Asgharzadeh et al. (2006) within the collection of 852 genes that were greater than 2-fold regulated by ZNF423 in the neuroblastoma cells. We performed 500.000 randomizations of the complete set of genes from the tumor study and determined how often genes that differentially expressed in the "ZNF423 high" versus the "ZNF423 low" tumors were encountered in the set of 852 genes at random. From these distributions we calculated the probability of finding 142 genes by summing the proportions of finding more than 142 genes at random.
Table S1. Sequences of Oligonucleotides
All relevant oligonucleotides used in this study are listed here. The sequences are all presented form 5' to 3'. The ZNF423 cut-off value of 353.6 was determined as described in Experimental Procedures. The list of 142 genes that were greater than 2-fold regulated by ZNF423 in the neuroblastoma cells and also were significantly differentially expressed (t-test p-value <0.01) in the "ZNF423 high" versus the "ZNF423 low" cohort of 102 neuroblastoma tumors (Asgharzadeh et al., 2006) .
